Literature DB >> 3578320

Ciprofloxacin increases serum levels of theophylline.

S Raoof, C Wollschlager, F A Khan.   

Abstract

During a clinical trial of orally administered ciprofloxacin in respiratory tract infections, changes in serum theophylline levels were evaluated in 33 hospitalized patients who also required theophylline therapy. Patients received intravenous theophylline in standard titrated doses and 750 mg of oral ciprofloxacin twice daily. Serum theophylline levels in all patients were measured before and during ciprofloxacin therapy. The mean serum pretreatment theophylline level was 7.8 +/- 4.6 micrograms/ml; during ciprofloxacin therapy, the level increased to 14.6 +/- 7.4 micrograms/ml. Twenty of the 33 (61 percent) patients evaluated had increases in serum theophylline levels by a mean value of 10.5 micrograms/ml. In 30 percent of patients who experienced increases, theophylline concentrations were in the toxic range. This occurred more frequently in elderly patients with chronic obstructive pulmonary disease. In light of the frequency and potential severity of this interaction, careful monitoring of serum theophylline levels in patients receiving theophylline and ciprofloxacin is recommended.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3578320

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

1.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Authors:  Kiyomi Ito; Koji Chiba; Masato Horikawa; Michi Ishigami; Naomi Mizuno; Jun Aoki; Yasumasa Gotoh; Takafumi Iwatsubo; Shin-ichi Kanamitsu; Motohiro Kato; Iichiro Kawahara; Kayoko Niinuma; Akiko Nishino; Norihito Sato; Yuko Tsukamoto; Kaoru Ueda; Tomoo Itoh; Yuichi Sugiyama
Journal:  AAPS PharmSci       Date:  2002

2.  Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.

Authors:  A Anadón; M R Martinez-Larrañaga; M C Fernandez; M J Diaz; P Bringas
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

4.  Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.

Authors:  M H Chandler; S M Toler; R P Rapp; R R Muder; J A Korvick
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 5.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 6.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

8.  The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.

Authors:  K T Batty; T M Davis; K F Ilett; L J Dusci; S R Langton
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

9.  Effect of norfloxacin on theophylline pharmacokinetics at steady state.

Authors:  S K Bowles; Z Popovski; M J Rybak; H B Beckman; D J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.